Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)

627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—

Results from Retrospective/Observational Studies: Front-Line Treatment and Prognostication of Burkitt Lymphoma Plasmablastic Lymphoma and DLBCL  

Watch Session

705 The Burkitt Lymphoma International Prognostic Index (BL-IPI)  according to ASH clinically relevant abstract

Adam J Olszewski, Lasse H. Jakobsen, Graham P. Collins, et al.

 

706 Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Juan Pablo Alderuccio, Adam J Olszewski, Andrew M. Evens, et al.

 

707 Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

Pietro R Di Ciaccio, Mark N. Polizzotto, Kate Cwynarski, et al.

 

708 Outcome Among Adolescents and Young Adults with Mature B-Cell Non Hodgkin Lymphoma at Pediatric Versus Adult Centers: A Population-Based Study Using the IMPACT Cohort

Sumit Gupta, Nancy Baxter, Rinku Sutradhar, et al.